| Gene | APOE |
| UniProt ID | [P02649](https://www.uniprot.org/uniprot/P02649) |
| PDB Structures | [1LE2](https://www.rcsb.org/structure/1LE2), [2L7B](https://www.rcsb.org/structure/2L7B) |
| Molecular Weight | 34.2 kDa |
| Amino Acids | 317 |
| Subcellular Location | Secreted, extracellular space |
| Protein Family | Apolipoprotein family |
Apolipoprotein E (APOE) is a 34 kDa secreted glycoprotein that serves as the primary cholesterol transport protein in the brain and plays a central role in lipid metabolism, synaptic repair, and neuroinflammation[1]. APOE is encoded by the APOE gene on chromosome 19q13.2 and exists as three major isoforms (ε2, ε3, ε4) that differ by single amino acid substitutions at positions 112 and 158[2]. The ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), increasing risk 3- to 15-fold in a dose-dependent manner[3].
APOE is produced primarily by astrocytes in the central nervous system, where it mediates cholesterol transport to neurons via LDL receptor family members, supporting synaptic plasticity and membrane repair[4]. Beyond lipid transport, APOE isoforms differentially modulate amyloid-β aggregation and clearance, tau pathology, neuroinflammation, and blood-brain barrier integrity[5].
APOE consists of two structural domains connected by a flexible hinge region[6]:
The Arg-112 substitution in APOE4 causes a domain interaction between the N- and C-terminal domains, altering lipid binding preferences and conformational stability[7]. This "molten globule" tendency contributes to:
APOE mediates cholesterol and phospholipid transport between glial cells and neurons via interactions with LDL receptor family members, including LDLR, LRP1, APOER2 (LRP8), and VLDLR[8]:
APOE facilitates synaptic remodeling and repair following injury through[9]:
Under normal conditions, APOE exerts neuroprotective effects via[10]:
APOE4 is the strongest genetic risk factor for late-onset AD, with multiple pathogenic mechanisms[11]:
APOE4 carriers show[15]:
APOE4 is a significant risk factor for DLB, potentially through synergistic effects on α-synuclein and Aβ pathology[16].
APOE4 carriers have worse outcomes after TBI, including[17]:
Structure correctors aim to disrupt pathological APOE4 domain interaction[18]:
APOE modulation strategies[19]:
APOE-targeted antibodies[20]:
ABCA1/ABCG1 upregulation[21]:
APOE2 mimetic peptides[22]:
| Interactor | Function | Disease Relevance |
|---|---|---|
| LDLR | Cholesterol uptake | Cardiovascular disease |
| LRP1 | Aβ clearance, signaling | AD, BBB function |
| APOER2/LRP8 | Reelin signaling, synaptic plasticity | AD, neurodevelopment |
| Amyloid-β | Aggregation, clearance | AD pathogenesis |
| Tau | Pathology modulation | Tauopathies |
| ABCA1 | Lipidation | Lipid metabolism |
| HSPG | Cell surface binding | Aβ clearance |
APOE is a central player in brain lipid metabolism and neurodegeneration, with APOE4 representing the strongest genetic risk factor for Alzheimer's disease. Its pleiotropic effects on Aβ metabolism, tau pathology, neuroinflammation, and vascular integrity make it an attractive therapeutic target. Current strategies focus on structure correction, isoform conversion, lipidation enhancement, and blocking pathological protein interactions.
Apolipoprotein E (Apoe) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1:1]
Apolipoprotein E (APOE[2])[1] (APOE[2]) is a lipid transport protein with major roles in cholesterol trafficking, synaptic maintenance, and injury response in the central nervous system. In the brain, APOE[2] is produced primarily by astrocytes, with additional contributions from microglia, and APOE[2]4 is the strongest common genetic risk factor for late-onset Alzheimer's disease[1:2] [2:1]
[2:2] [3:1]
. [4:1]
APOE[2] biology now sits at the intersection of The Amyloid Cascade Hypothesis, Tau Pathology], vascular dysfunction, and neuroimmune signaling. Rather than acting through a single pathway, APOE[2] genotype appears to shape multiple converging disease processes, including amyloid-beta deposition/clearance, tau]-mediated neurodegeneration, glial activation states, and Blood-Brain Barrier integrity[3:2] [5:1]
[4:2] [6:1]
. [7:1]
APOE[2] is encoded on chromosome 19q13.32 and produces a 299-amino-acid apolipoprotein that binds lipids and members of the LDL receptor family. Two coding polymorphisms define the major isoforms. APOE[2]3 is the most common allele globally and is generally considered neutral-risk relative to APOE[2]4. APOE[2]2 is often associated with reduced AD risk but can be linked to other lipid disorders. APOE[2]4 differs structurally in a way that influences domain interaction, lipidation behavior, receptor binding, and proteolytic susceptibility[3:3] [8:1]
[5:2] [9:1]
. [10:1]
In the central nervous system, APOE[2]-containing lipoprotein particles support membrane repair and synaptic remodeling. APOE[2] function is tightly tied to lipid transport machinery including ATP-binding cassette transporters and receptor pathways in neurons and glia. In disease states, isoform-dependent differences in lipid delivery and cellular stress responses may lower neuronal resilience and shift glial programs toward pro-inflammatory profiles[4:3] [11:1]
[6:2] [12:1]
. [13:1]
Landmark genetic studies in 1993 established APOE[2]4 as a major determinant of late-onset AD risk, with dose-dependent effects where risk rises and mean age at onset falls as APOE[2]4 copy number increases[1:3] [14:1]
[2:3] [15:1]
. Since then, population, biomarker, and neuropathology studies have repeatedly validated APOE[2]4 as a central susceptibility allele across sporadic and familial late-onset disease contexts[7:2] [16:1]
[8:2]
.
Recent analyses further suggest that homozygous APOE[2]4 carriers follow relatively predictable preclinical biomarker trajectories with earlier amyloid positivity and higher pathological burden, though penetrance, timing, and clinical phenotype remain influenced by ancestry, sex, vascular comorbidity, and additional genetic/environmental modifiers[8:3]
[9:2]
. This has important implications for risk stratification, prevention trials, and therapeutic safety monitoring.
APOE[2] genotype strongly influences amyloid and clearance kinetics. APOE[2]4 has been associated with reduced extracellular A-beta clearance and enhanced plaque deposition relative to APOE[2]3/APOE[2]2, consistent with both animal and human data[3:4]
[10:2]
. APOE[2] may also modulate microglial and perivascular clearance routes, affecting soluble versus deposited peptide pools over long preclinical windows.
APOE[2] effects are not limited to amyloid. Human and experimental studies suggest APOE[2]4 can amplify tau-mediated injury and network dysfunction, potentially through glial signaling, lipid dysregulation, and altered neuronal stress responses[4:4]
[11:2]
. This has supported models where APOE[2] acts as a systems-level modifier of disease progression beyond initial amyloid seeding.
APOE[2] influences innate immune programs in microglia/astrocytes, including transitions toward disease-associated cellular states linked to synapse loss and chronic inflammation[6:3]
[12:2]
. Isoform-specific signaling through receptor pathways and lipid handling appears central to these effects.
APOE[2]4 has been associated with Blood-Brain Barrier dysfunction, altered cerebrovascular reactivity, and interactions with metabolic risk factors, which may compound neurodegenerative trajectories[5:3]
[13:2]
. These mechanisms are increasingly relevant in mixed-pathology older adults where vascular and neurodegenerative changes coexist.
APOE[2] genotyping is widely used in research and increasingly informs trial enrichment and adverse-event risk monitoring for anti-amyloid therapies, especially because APOE[2]4 carriage is associated with elevated risk of amyloid-related imaging abnormalities (ARIA) in several antibody programs[14:2]
[15:2]
. In routine clinical care, APOE[2] status is usually interpreted as probabilistic risk information rather than deterministic diagnosis.
From a therapeutic perspective, APOE[2]-directed strategies are being explored across multiple modalities: APOE[2] expression modulation, lipidation enhancement, receptor-pathway targeting, antisense/gene-editing approaches, and therapies intended to uncouple APOE[2]4 from toxic downstream signaling[5:4]
[16:2]
. A key translational challenge is preserving essential APOE[2] lipid transport functions while reducing disease-amplifying effects.
Current APOE[2] research is moving toward precision frameworks that integrate genotype, plasma/CSF biomarkers, imaging profiles, and cell-type-resolved molecular signatures. Priorities include (1) clarifying causal mechanisms of APOE[2]4 in human tissue contexts, (2) defining protective pathways in resilient APOE[2]4 carriers, (3) improving ancestry-diverse risk models, and (4) testing early intervention windows before irreversible synaptic and network injury[9:3]
[12:3]
[16:3]
.
Beyond genotype-level risk estimates, APOE[2] isoform effects vary across cellular compartments and vascular niches. astrocytes and microglia regulate APOE[2] lipidation state, which in turn influences amyloid-beta uptake and immune tone[3:5]
[5:5]
. APOE[2]4-associated vascular dysfunction and Blood-Brain Barrier fragility are increasingly linked to earlier cognitive decline and mixed-pathology trajectories, supporting allele-informed biomarker interpretation and prevention trial design[4:5]
[7:3]
.
The study of Apolipoprotein E (Apoe) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mahley RW. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. PNAS. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Weisgraber KH, Rall SC, Mahley RW. Human E apoprotein heterogeneity. Journal of Biological Chemistry. 1981. ↩︎ ↩︎ ↩︎ ↩︎
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease. Science. 1993. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Pitas RE, Boyles JK, Lee SH, et al. Astrocytes synthesize apolipoprotein E. Journal of Biological Chemistry. 1987. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chen J, Li Q, Wang J. Topology of human apolipoprotein E3. Biochemistry. 2011. ↩︎ ↩︎ ↩︎ ↩︎
Dong LM, Weisgraber KH. Human apolipoprotein E4 domain interaction. Journal of Biological Chemistry. 1996. ↩︎ ↩︎ ↩︎ ↩︎
Herz J, Chen Y, Masiulis I, Zhou L. Expanding functions of lipoprotein receptors. Journal of Lipid Research. 2009. ↩︎ ↩︎ ↩︎ ↩︎
Mauch DH, Nägler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001. ↩︎ ↩︎ ↩︎ ↩︎
Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity. Nature Genetics. 1996. ↩︎ ↩︎ ↩︎
Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease. Nature Reviews Neurology. 2019. ↩︎ ↩︎ ↩︎
Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration. Nature. 2017. ↩︎ ↩︎ ↩︎ ↩︎
Zhu Y, Nwabuisi-Heath E, Dumanis SB, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Journal of Neuroscience. 2012. ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012. ↩︎ ↩︎ ↩︎
Huang X, Chen PC, Poole C. APOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004. ↩︎ ↩︎ ↩︎
Tsuang DW, DiGiacomo L, Bird TD. The APOE ε4 allele and dementia with Lewy bodies. Neurology. 2005. ↩︎ ↩︎ ↩︎ ↩︎
Zhou W, Xu D, Peng X, et al. Association of APOE genotype with risk of post-traumatic stress disorder. Scientific Reports. 2018. ↩︎
Chen HK, Ji ZS, Dodson SE, et al. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria. Journal of Biological Chemistry. 2011. ↩︎
Litvinchuk A, Suh JH, Guo JL, et al. Apolipoprotein E4 reduction with antisense oligonucleotides. Journal of Clinical Investigation. 2021. ↩︎
Liao F, Hori Y, Hudry E, et al. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation. Journal of Neuroscience. 2014. ↩︎
Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear β-amyloid. Science. 2012. ↩︎
Laskowitz DT, Thekdi AD, Thekdi SD, et al. [Downregulation of microglial activation by apolipoprotein E](https://doi.org/10.1016/S0165-5728(00). Journal of Neuroimmunology. 2001. ↩︎